JP2015522018A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015522018A5 JP2015522018A5 JP2015520304A JP2015520304A JP2015522018A5 JP 2015522018 A5 JP2015522018 A5 JP 2015522018A5 JP 2015520304 A JP2015520304 A JP 2015520304A JP 2015520304 A JP2015520304 A JP 2015520304A JP 2015522018 A5 JP2015522018 A5 JP 2015522018A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- compound according
- acceptable salt
- compound
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 27
- 150000003839 salts Chemical class 0.000 claims description 16
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 description 4
- 238000000034 method Methods 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261665951P | 2012-06-29 | 2012-06-29 | |
| US61/665,951 | 2012-06-29 | ||
| US201361779099P | 2013-03-13 | 2013-03-13 | |
| US61/779,099 | 2013-03-13 | ||
| PCT/US2013/046684 WO2014004229A1 (en) | 2012-06-29 | 2013-06-20 | Phenoxyethyl piperidine compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015522018A JP2015522018A (ja) | 2015-08-03 |
| JP2015522018A5 true JP2015522018A5 (enExample) | 2016-08-04 |
| JP6127136B2 JP6127136B2 (ja) | 2017-05-10 |
Family
ID=48746666
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015520304A Active JP6127136B2 (ja) | 2012-06-29 | 2013-06-20 | フェノキシエチルピペリジン化合物 |
Country Status (42)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR091429A1 (es) * | 2012-06-29 | 2015-02-04 | Lilly Co Eli | Compuestos de fenoxietil piperidina |
| TWI636046B (zh) | 2013-05-17 | 2018-09-21 | 美國禮來大藥廠 | 苯氧基乙基二氫－１ｈ－異喹啉化合物 |
| CN105793242B (zh) * | 2013-12-17 | 2018-02-16 | 伊莱利利公司 | 苯氧基乙基环状胺衍生物及其作为ep4受体调节剂的活性 |
| CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
| AU2018268311B2 (en) | 2017-05-18 | 2022-02-10 | Idorsia Pharmaceuticals Ltd | Pyrimidine derivatives as PGE2 receptor modulators |
| TW201900180A (zh) | 2017-05-18 | 2019-01-01 | 瑞士商愛杜西亞製藥有限公司 | 嘧啶衍生物 |
| CN110612296A (zh) | 2017-05-18 | 2019-12-24 | 爱杜西亚药品有限公司 | 作为pge2受体调节剂的苯基衍生物 |
| JP7093791B2 (ja) | 2017-05-18 | 2022-06-30 | イドーシア ファーマシューティカルズ リミテッド | Ｐｇｅ２レセプター調節剤としてのベンゾフラン及びベンゾチオフェン誘導体 |
| MX394108B (es) | 2017-05-18 | 2025-03-21 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituidos. |
| CN111989311B (zh) * | 2019-01-22 | 2022-03-22 | 凯复(苏州)生物医药有限公司 | 抑制pge2/ep4信号传导的化合物、其制备方法及其在医药上的应用 |
| KR20230107228A (ko) | 2020-11-13 | 2023-07-14 | 오노 야꾸힝 고교 가부시키가이샤 | Ep4 길항약과 면역 체크포인트 저해 물질의 병용에 의한 암 치료 |
| GB202211232D0 (en) | 2022-08-02 | 2022-09-14 | Heptares Therapeutics Ltd | Prostaglandin EP4 receptor agonist compounds |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2500157C2 (de) | 1975-01-03 | 1983-09-15 | Hoechst Ag, 6230 Frankfurt | N-Acyl-4-(2-aminoäthyl)-benzoesäuren, deren Salze und Ester, Verfahren zu deren Herstellung und deren Verwendung |
| WO2003077910A1 (en) * | 2002-03-18 | 2003-09-25 | Pfizer Products Inc. | Methods of treatment with selective ep4 receptor agonists |
| BRPI0406717A (pt) * | 2003-01-10 | 2005-12-20 | Hoffmann La Roche | Composto, composição farmacêutica que compreende o mesmo, método de tratamento de uma enfermidade em um mamìfero, utilização do composto e processo para a sua produção |
| RS20060143A (sr) * | 2003-09-03 | 2008-06-05 | Pfizer Inc., | Jedinjenja fenil ili piridil amida kao antagonisti prostaglandina e2 |
| US20050105732A1 (en) | 2003-11-17 | 2005-05-19 | Hutchings George T. | Systems and methods for delivering pre-encrypted content to a subscriber terminal |
| CN1950334A (zh) | 2004-05-04 | 2007-04-18 | 辉瑞有限公司 | 邻位取代的芳基或杂芳基酰胺化合物 |
| MXPA06011555A (es) * | 2004-05-04 | 2006-12-15 | Pfizer | Compuestos de metil-aril o heteroaril-amida sustituida. |
| US7592364B2 (en) * | 2006-02-28 | 2009-09-22 | Allergan, Inc. | Substituted gamma lactams as therapeutic agents |
| CA2648729A1 (en) | 2006-04-24 | 2007-11-01 | Merck Frosst Canada Ltd. | Indole amide derivatives as ep4 receptor antagonists |
| US7705035B2 (en) | 2006-06-12 | 2010-04-27 | Merck Frosst Canada Ltd. | Indoline amide derivatives as EP4 receptor ligands |
| WO2008092860A1 (en) * | 2007-01-30 | 2008-08-07 | Janssen Pharmaceutica N.V. | Bicyclic derivatives as ep4 agonists |
| US8598355B2 (en) * | 2008-05-14 | 2013-12-03 | Astellas Pharma Inc. | Amide compound |
| US8404736B2 (en) | 2008-08-14 | 2013-03-26 | Beta Pharma Canada Inc. | Heterocyclic amide derivatives as EP4 receptor antagonists |
| BR112012020236A2 (pt) | 2010-02-22 | 2016-05-17 | Raqualia Pharma Inc | uso de um composto com atividade antagonística de ep4 ou um sal farmaceuticamente aceitável do mesmo, uso de um composto da fórmula (i), (ii), (iii), (iv), (va) ou (vb), ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica e método para o tratamento de doenças mediadas por il-23 em um sujeito animal, incluindo um sujeito mamífero |
| EP3061751A1 (en) * | 2010-09-21 | 2016-08-31 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition |
| RU2565596C2 (ru) | 2011-07-04 | 2015-10-20 | Роттафарм Биотек С.Р.Л. | Производные циклических аминов в качестве антагонистов рецептора ер4 |
| ES2564353T3 (es) * | 2011-07-04 | 2016-03-22 | Rottapharm Biotech S.R.L. | Derivados de aminas cíclicas como agonistas de los receptores EP4 |
| AR091429A1 (es) * | 2012-06-29 | 2015-02-04 | Lilly Co Eli | Compuestos de fenoxietil piperidina |
-
2013
- 2013-06-13 AR ARP130102076 patent/AR091429A1/es active IP Right Grant
- 2013-06-13 JO JOP/2013/0177A patent/JO3296B1/ar active
- 2013-06-14 TW TW102121220A patent/TWI599561B/zh active
- 2013-06-20 EA EA201492255A patent/EA024392B1/ru not_active IP Right Cessation
- 2013-06-20 MX MX2014015953A patent/MX345324B/es active IP Right Grant
- 2013-06-20 JP JP2015520304A patent/JP6127136B2/ja active Active
- 2013-06-20 CA CA2875569A patent/CA2875569C/en active Active
- 2013-06-20 DK DK13734248.1T patent/DK2867207T3/en active
- 2013-06-20 KR KR1020147036137A patent/KR101653476B1/ko active Active
- 2013-06-20 EP EP13734248.1A patent/EP2867207B1/en active Active
- 2013-06-20 LT LTEP13734248.1T patent/LT2867207T/lt unknown
- 2013-06-20 PL PL13734248T patent/PL2867207T3/pl unknown
- 2013-06-20 CN CN201380034168.8A patent/CN104411684B/zh active Active
- 2013-06-20 US US13/922,278 patent/US8962659B2/en active Active
- 2013-06-20 UA UAA201413598A patent/UA114325C2/uk unknown
- 2013-06-20 RS RS20171039A patent/RS56452B1/sr unknown
- 2013-06-20 PE PE2014002532A patent/PE20150182A1/es active IP Right Grant
- 2013-06-20 ME MEP-2017-223A patent/ME02840B/me unknown
- 2013-06-20 HR HRP20171515TT patent/HRP20171515T1/hr unknown
- 2013-06-20 BR BR112014031616-3A patent/BR112014031616B1/pt active IP Right Grant
- 2013-06-20 AP AP2014008164A patent/AP2014008164A0/xx unknown
- 2013-06-20 SI SI201330755T patent/SI2867207T1/sl unknown
- 2013-06-20 ES ES13734248.1T patent/ES2644812T3/es active Active
- 2013-06-20 MA MA37686A patent/MA37686B1/fr unknown
- 2013-06-20 MY MYPI2014703971A patent/MY173878A/en unknown
- 2013-06-20 AU AU2013280875A patent/AU2013280875B2/en active Active
- 2013-06-20 SG SG11201408641UA patent/SG11201408641UA/en unknown
- 2013-06-20 PT PT137342481T patent/PT2867207T/pt unknown
- 2013-06-20 HU HUE13734248A patent/HUE034425T2/en unknown
- 2013-06-20 WO PCT/US2013/046684 patent/WO2014004229A1/en not_active Ceased
- 2013-06-20 NZ NZ701933A patent/NZ701933A/en unknown
-
2014
- 2014-11-24 ZA ZA2014/08632A patent/ZA201408632B/en unknown
- 2014-11-27 CO CO14261550A patent/CO7151507A2/es unknown
- 2014-11-28 TN TN2014000501A patent/TN2014000501A1/fr unknown
- 2014-12-03 CR CR20140553A patent/CR20140553A/es unknown
- 2014-12-11 IL IL236219A patent/IL236219A/en active IP Right Grant
- 2014-12-17 GT GT201400288A patent/GT201400288A/es unknown
- 2014-12-17 DO DO2014000287A patent/DOP2014000287A/es unknown
- 2014-12-26 CL CL2014003535A patent/CL2014003535A1/es unknown
- 2014-12-29 EC ECIEPI201433267A patent/ECSP14033267A/es unknown
-
2015
- 2015-01-05 PH PH12015500009A patent/PH12015500009B1/en unknown
- 2015-01-13 US US14/595,350 patent/US9402838B2/en active Active
-
2017
- 2017-09-15 CY CY20171100979T patent/CY1119425T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY167423A (en) | Quinoline carboxamide and quinoline carbonitrile derivatives as mglur2-negative allosteric modulators,compositions,and their use | |
| JP2016508134A5 (enExample) | ||
| CY1119490T1 (el) | Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων | |
| RU2018110647A (ru) | Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний | |
| JP2016527217A5 (enExample) | ||
| JP2016536286A5 (enExample) | ||
| JP2015522589A5 (enExample) | ||
| JP2019515908A5 (enExample) | ||
| EA201270144A1 (ru) | Комбинированная терапия при лечении диабета | |
| RU2017114346A (ru) | АНТАГОНИСТЫ ИНТЕГРИНА ανβ6 | |
| JP2016528301A5 (enExample) | ||
| EA201492010A1 (ru) | Применение высокой дозы лахинимода для лечения рассеянного склероза | |
| JP2016522254A5 (enExample) | ||
| RU2016150326A (ru) | Производные изоиндолина для применения в лечении вирусной инфекции | |
| JP2016510326A5 (enExample) | ||
| JP2019505529A5 (enExample) | ||
| RU2017103656A (ru) | Производные изоиндолинона, полезные в качестве противовирусных средств | |
| JP2015522033A5 (enExample) | ||
| RU2019100037A (ru) | Способ лечения рассеянного склероза с использованием ингибитора lsd1 | |
| JP2015516419A5 (enExample) | ||
| ME02840B (me) | Spojevi fenoksietilpiperidina | |
| RU2017134285A (ru) | Борсодержащие низкомолекулярные соединения как антипротозойные агенты | |
| RU2016151973A (ru) | Пиридиноны, замещенные фенилом и трет-бутилуксусной кислотой, обладающие анти-вич эффектами | |
| JP2014530204A5 (enExample) | ||
| RU2020120156A (ru) | Лечение приливов и потери костной ткани, вызванных андрогенной депривационной терапией с применением цис-кломифена |